Efficacy of PEG-IFN alfa-2b plus Ribabirin and HMG-CoA reductase inhibitor combination antiviral therapy ; pilot study

Efficacy of PEG-IFN alfa-2b plus Ribabirin and HMG-CoA reductase inhibitor combination antiviral therapy ; pilot study - Efficacy of PEG-IFN alfa-2b plus Ribabirin and HMG-CoA reductase inhibitor combination therapy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000000713

Enrollment

Registered

2007-05-09

Start date

2006-12-01

Completion date

Unknown

Last updated

2025-07-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic hepatitis C

Interventions

HMG-CoA reductase inhibitor

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria:

Exclusion criteria

Exclusion criteria: 1) Patients receiving shosaiko-to 2) Autoimmune hepatitis 3) History of hypersensitivity to PEG-IFN alpha-2b or other interferons 4) History of hypersensitivity to biological products such as vaccine 5) Decompenstated liver cirrhosis 6) HCC, malignat tumor 7) With or with a history of severe psychosis such as severe depression, suicidal ideation or attempt, etc. 8) Pregnant or lactating women and women who may be pregnant 9) Judged by investigator not to be appropriate for inclusion in this study

Design outcomes

Primary

Measure	Time frame
virologic response	—

Countries

Japan

Contacts

Public ContactTomokazu Kawaoka

graduate school of biomedical science, Hiroshima university Department and medicine and molecular science

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Feb 4, 2026